Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia

ClinicalTrials.gov ID: NCT00551148

Public ClinicalTrials.gov record NCT00551148. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

PD 0200390 Dose-ranging Trial: A Randomized, Double-blind, Placebo-controlled, 5-way Crossover, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to further explore an effective dose range of PD0200390 for the treatment of patients with insomnia.

Study identification

NCT ID
NCT00551148
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
92 participants

Conditions and interventions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
18 Years to 64 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 2007 (Type not available)
Primary completion
Jan 2008 (Actual)
Completion
Jan 2008 (Actual)
Last update posted
Jul 25, 2012

2007 – 2008

United States locations

U.S. sites
16
U.S. states
9
U.S. cities
15
Facility City State ZIP Site status
Pfizer Investigational Site Glendale Arizona 85306 —
Pfizer Investigational Site Phenoix Arizona 85006 —
Pfizer Investigational Site Phoenix Arizona 85006 —
Pfizer Investigational Site Tucson Arizona 85712 —
Pfizer Investigational Site San Diego California 92103 —
Pfizer Investigational Site Miami Florida 33143 —
Pfizer Investigational Site Naples Florida 34110 —
Pfizer Investigational Site South Miami Florida 33143 —
Pfizer Investigational Site Atlanta Georgia 30328 —
Pfizer Investigational Site Atlanta Georgia 30342 —
Pfizer Investigational Site Overland Park Kansas 66212 —
Pfizer Investigational Site Crestview Hills Kentucky 41017 —
Pfizer Investigational Site New York New York 10019 —
Pfizer Investigational Site Cary North Carolina 27511 —
Pfizer Investigational Site Raleigh North Carolina 27612 —
Pfizer Investigational Site Cincinnati Ohio 45227 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00551148, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 25, 2012 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00551148 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →